Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Industry Sponsorship and Research Outcome

Industry Sponsorship and Research Outcome EVIDENCE TO PRACTICE A Cochrane Review SOURCE OF REVIEW favorable to the sponsor’s prod- results (RR, 1.87 [95% CI, 1.54- 1,4,5 uct. There are several potential 2.27]), meaning that the industry- This review is an update of an ear- ways that industry sponsors can in- sponsored studies showed less lier review of studies examining the fluence the outcome of a study, in- evidence of harm. The reports of association of pharmaceutical in- cluding how the question is framed, industry-sponsored studies also dustry sponsorship of drug studies how the study is designed and con- presented more favorable overall and research outcomes. The re- ducted, the way data are analyzed, conclusions (RR, 1.31 [95% CI, 1.20- view was converted to a Cochrane selective reporting of favorable re- 1.44]) compared with non–industry- 5-7 Methodology Review, updated to sults, and spin in conclusions. It sponsored studies, and the results double the number of included stud- is not clear which, if any, of these and conclusions sections in these ar- ies, and the scope was expanded to methodological considerations ex- ticles were less likely to be in agree- include device studies. The review plain the association of industry ment with each other. In addition, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Industry Sponsorship and Research Outcome

JAMA Internal Medicine , Volume 173 (7) – Apr 8, 2013

Loading next page...
 
/lp/american-medical-association/industry-sponsorship-and-research-outcome-UasI0RJhuD
Publisher
American Medical Association
Copyright
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2013.4190
pmid
23440226
Publisher site
See Article on Publisher Site

Abstract

EVIDENCE TO PRACTICE A Cochrane Review SOURCE OF REVIEW favorable to the sponsor’s prod- results (RR, 1.87 [95% CI, 1.54- 1,4,5 uct. There are several potential 2.27]), meaning that the industry- This review is an update of an ear- ways that industry sponsors can in- sponsored studies showed less lier review of studies examining the fluence the outcome of a study, in- evidence of harm. The reports of association of pharmaceutical in- cluding how the question is framed, industry-sponsored studies also dustry sponsorship of drug studies how the study is designed and con- presented more favorable overall and research outcomes. The re- ducted, the way data are analyzed, conclusions (RR, 1.31 [95% CI, 1.20- view was converted to a Cochrane selective reporting of favorable re- 1.44]) compared with non–industry- 5-7 Methodology Review, updated to sults, and spin in conclusions. It sponsored studies, and the results double the number of included stud- is not clear which, if any, of these and conclusions sections in these ar- ies, and the scope was expanded to methodological considerations ex- ticles were less likely to be in agree- include device studies. The review plain the association of industry ment with each other. In addition,

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Apr 8, 2013

References